| | 1616391-65-1 Basic information More.. |
| Product Name: | EPZ015666 | | Synonyms: | EPZ015666;(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide;GSK3235025;GSK-3235025;N-[(2S)-3-(3,4-Dihydro-2(1H)-isoquinolinyl)-2-hydroxypropyl]-6-(3-oxetanylamino)-4-pyrimidinecarboxamide;N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide;EPZ-015666;EPZ 015666;GSK3235025;GSK3235025 (EPZ015666) | | CAS: | 1616391-65-1 | | MF: | C20H25N5O3 | | MW: | 383.44 | | EINECS: | | | Mol File: | 1616391-65-1.mol |  |
Use
EPZ015666 (GSK3235025) is an orally available inhibitor of protein arginine methyltransferase-5 (PRMT5), which is involved in diverse cellular processes, including tumorigenesis, and its overexpression is observed in cell lines and primary patient samples derived from lymphomas, particularly mantle cell lymphoma (MCL).EPZ015666 showed dose-dependent antitumor activity in multiplein vitroandin vivomantle cell lymphoma (MCL) models with treatment of MCL cell lines leading to inhibition of SmD3 methylation and cell death. Therefore, it is a potential drug candidate for future cancer therapy.
- EPZ015666
-
- US $56.00-126.00 / mg
- 2025-10-26
- CAS:1616391-65-1
- Min. Order:
- Purity: 99.36%
- Supply Ability: 10g
|
|
1616391-65-1
Recommend Suppliers |
|